Litcius/Paper detail

The Potential Diagnostic and Prognostic Value of Circulating MicroRNAs in the Assessment of Patients With Prostate Cancer: Rational and Progress

Elham Samami, Ghazaleh Pourali, Mahla Arabpour, Azar Fanipakdel, Soodabeh Shahidsales, Seyed Alireza Javadinia, Seyed Mahdi Hassanian, Saeid Mohammadparast, Amir Avan

2022Frontiers in Oncology14 citationsDOIOpen Access PDF

Abstract

Prostate cancer (P.C.) is one of the most frequent diagnosed cancers among men and the first leading cause of death with an annual incidence of 1.4 million worldwide. Prostate-specific antigen is being used for screening/diagnosis of prostate disease, although it is associated with several limitations. Thus, identification of novel biomarkers is warranted for diagnosis of patients at earlier stages. MicroRNAs (miRNAs) are recently being emerged as potential biomarkers. It has been shown that these small molecules can be circulated in body fluids and prognosticate the risk of developing P.C. Several miRNAs, including MiR-20a, MiR-21, miR-375, miR-378, and miR-141, have been proposed to be expressed in prostate cancer. This review summarizes the current knowledge about possible molecular mechanisms and potential application of tissue specific and circulating microRNAs as diagnosis, prognosis, and therapeutic targets in prostate cancer.

Topics & Concepts

Prostate cancerMedicinemicroRNADiseaseCancerProstateOncologyProstate-specific antigenBiomarkerDiagnostic biomarkerInternal medicineBioinformaticsBiologyGeneBiochemistryMicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseases